Patient demographics and therapy response
Patient . | Cohort . | Age . | Sex . | Stage at enrollment . | Histology . | Prior RT . | Prior therapy . | Lymphoma involvement of BM . | Response . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | A | 59 | F | III | Mantle cell | No | CHOP, BMT (Auto) | No | CR |
| 2 | A | 61 | M | IV | Mantle cell | Yes | CHOP, FDR, FDR/MTX, ESHAP, MINE, RTX, ICE | Yes | PD |
| 3 | A | 63 | F | III | Follicular | No | CHOP, FDR, RTX | No | PR |
| 4 | B | 57 | F | IV | Mantle cell | No | CHOP, RTX, FDR, ESHAP | Yes | SD |
| 5 | B | 72 | M | IV | Mantle cell | Yes | CHOP, RTX, MINE, RTX, DHAP | Yes | PD |
| 6 | B | 61 | M | III | Mantle cell | No | FDR/MTX, RTX, FDR | No | SD |
| 7 | B | 68 | F | III | DLCL | No | CHOP/RTX, ICE | Yes | NE |
| 8 | B | 52 | M | III | DLCL | Yes | CHOP, RTX, DHAP, ICE | No | PD |
| 9 | C | 50 | M | IV | Mantle cell | No | CHOP | Yes | PD |
| 10 | C | 77 | M | IV | Follicular | Yes | CHOP/RTX, VP-16/MTX/PRD, FDR | Yes | PD |
| 11 | C | 35 | M | IV | DLCL | Yes | CHOP, RTX, ICE, BMT (Auto) | No | PD |
| 12 | C | 53 | M | IV | SLL | No | CHOP/RTX | No | CR |
| 13 | D | 38 | F | II | Follicular | No | FDR/MTX | No | SD |
| 14 | D | 53 | M | III | Follicular | No | CVP, FDR/MTX/DCD | No | PD |
| 15 | D | 80 | F | IV | Mantle cell | No | CP (×4), CHOP/R | No | PD |
Patient . | Cohort . | Age . | Sex . | Stage at enrollment . | Histology . | Prior RT . | Prior therapy . | Lymphoma involvement of BM . | Response . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | A | 59 | F | III | Mantle cell | No | CHOP, BMT (Auto) | No | CR |
| 2 | A | 61 | M | IV | Mantle cell | Yes | CHOP, FDR, FDR/MTX, ESHAP, MINE, RTX, ICE | Yes | PD |
| 3 | A | 63 | F | III | Follicular | No | CHOP, FDR, RTX | No | PR |
| 4 | B | 57 | F | IV | Mantle cell | No | CHOP, RTX, FDR, ESHAP | Yes | SD |
| 5 | B | 72 | M | IV | Mantle cell | Yes | CHOP, RTX, MINE, RTX, DHAP | Yes | PD |
| 6 | B | 61 | M | III | Mantle cell | No | FDR/MTX, RTX, FDR | No | SD |
| 7 | B | 68 | F | III | DLCL | No | CHOP/RTX, ICE | Yes | NE |
| 8 | B | 52 | M | III | DLCL | Yes | CHOP, RTX, DHAP, ICE | No | PD |
| 9 | C | 50 | M | IV | Mantle cell | No | CHOP | Yes | PD |
| 10 | C | 77 | M | IV | Follicular | Yes | CHOP/RTX, VP-16/MTX/PRD, FDR | Yes | PD |
| 11 | C | 35 | M | IV | DLCL | Yes | CHOP, RTX, ICE, BMT (Auto) | No | PD |
| 12 | C | 53 | M | IV | SLL | No | CHOP/RTX | No | CR |
| 13 | D | 38 | F | II | Follicular | No | FDR/MTX | No | SD |
| 14 | D | 53 | M | III | Follicular | No | CVP, FDR/MTX/DCD | No | PD |
| 15 | D | 80 | F | IV | Mantle cell | No | CP (×4), CHOP/R | No | PD |
CR indicates complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; BMT, bone marrow transplantation; FDR, fludarabine; MTX, mitoxantrone; ESHAP, etoposide, methylprednisolone, cytarabine, cisplatin; MINE, methyl-gag, ifosfamide, methotrexate, and etoposide; RTX, rituxan; ICE, ifosfamide, cytarabine, etoposide; DHAP, cisplatin, cytarabine, dexamethasone; CP, chlorambucil, prednisone.